• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Boehringer Ingelheim touts Spiolto Respimat inhaler data

October 2, 2019 By Sean Whooley

Boehringer IngelheimBoehringer Ingelheim said yesterday that results from a study of its Spiolto Respimat inhaler showed benefits including improving symptoms and lung function in treating chronic obstructive pulmonary disease.

The Spiolto Respimat is a soft-mist inhaler designed for the treatment of airflow obstruction in patients with COPD.

A pooled analysis exploring COPD treatment with the tiotropium-based Spiolto Respimat showed optimizing bronchodilation with tiotropium/olodaterol led to improvements in lung function, health status and breathlessness. A comparative analysis found that the treatment surpassed all others in terms of efficacy, while also producing fewer serious adverse cardiovascular events.

The studies also showed a high level of satisfaction with the usability of the inhalers, as the company said data reinforces the importance of patient needs and preferences. According to Boehringer Ingelheim, 52% of COPD patients struggle to inhale from their device, and the company highlighted the Spiolto Respimat’s usability as a key factor in COPD management.

Boehringer Ingelheim presented data from 11 abstracts relating to the COPD portfolio at the European Respiratory Society (ERS) 2019 Congress over the past five days.

“The importance of matching a specific inhaled therapy with patients’ personal needs and preferences cannot be overstated in COPD management,” Dr. Paola Rogliani,of Rome’s Policlinico Tor Vergata, said in prepared remarks. “A novel bidimensional, pooled analysis enabled us to directly compare six LAMA/LABA fixed-dose combinations and demonstrate that tiotropium/olodaterol improved patient outcomes more than the other treatments in the class. Varying efficacy and safety of combinations in the same class should be considered for a patient-centred approach in COPD.”

“As a company, we have been developing therapies and inhaler devices for people with respiratory conditions for almost a century,” added Boehringer Ingelheim global head of medical affairs Dr. Alberto de la Hoz. “The data presented at ERS underscore the efficacy of tiotropium/olodaterol as a treatment for COPD patients with different clinical characteristics and needs, and how the Respimat re-usable was enhanced based on HCP and patient feedback, addressing their evolving needs and preferences.”

Filed Under: Clinical Trials, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS